ClinicalTrials.gg
Active, not recruitingNCT04075266Updated Nov 9, 2026Results posted

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

A Phase 2 interventional study of Ocrelizumab in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 12 sites in 3 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
24th of 27
23 · median 170
Started
2020
with 4 others
Phase 2
Only one
of the 27
Primary completion
2023-10
later than 0 of 13 live
Registered
9th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 24th largest by enrollment, is one of 5 that started in 2020, is the only one in phase 2, reaches primary completion later than 0 of the 13 other live ones, and was the 9th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This 12-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at screening between =/>10 to \<18 years
  • Body weight >/= 25 kg
  • Children and adolescents must have received all childhood required vaccinations
  • Female participants of must agree to either remain completely abstinent or to use reliable means of
  • Diagnosis of relapsing-remitting multiple sclerosis (RRMS)
  • Expanded Disability Status Scale (EDSS) at screening: 0-5.5, inclusive
  • Participants naive to prior disease-modifying therapy (DMT)
  • Participants who have had at least 6 contiguous months of DMT within the past 1 year must have evidence of disease activity occurring after the full 6-month course of treatment, that is, at least one relapse or >/= 1 Gd-enhancing lesion(s) on a T1-weighted brain MRI

Exclusion criteria

Exclusion Criteria:

  • Known presence or suspicion of other neurologic disorders that may mimic MS, including, but not limited to, acute disseminated encephalomyelitis, neuromyelitis optica or neuromyelitis optica spectrum disorders and any neurologic, somatic, or metabolic condition that could interfere with brain function or normal cognitive or neurological development
  • Patients that are aquaporin 4 positive and myelin oligodendrocyte glycoprotein (MOG) antibody positive are not eligible to participate in the study.
  • In case of an acute disseminated encephalomyelitis (ADEM)like appearance of the first MS attack, a second attack with clear MS-like features is required.
  • Infection requiring hospitalization or treatment with IV anti-infective agents
  • History or known presence of recurrent or chronic infection (e.g., , syphilis, tuberculosis)
  • Receipt of a live or within 6 weeks prior to treatment allocation
  • History or laboratory evidence of coagulation disorders
  • Peripheral venous access that precludes IV administration and venous blood sampling
  • Inability to complete a magnetic resonance imaging (MRI) scan
  • History of cancer, including solid tumors, hematologic , and carcinoma in situ
  • History of a severe allergic or anaphylactic reaction to humanized or murine monoclonal antibody (mAbs) or known to any component of ocrelizumab solution
  • Previous treatment with B-cell-targeted therapies
  • Percentage of CD4 \< 30%
  • \< 1.5x1000/microliter
  • Lymphocyte count below the lower limit of normal (LLN) for age- and sex-specific reference range
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants with a body weight from \>/= 25 kg to \< 40 kg (with at least 2 participants with a body weight from \>/= 25 kg to \</= 35 kg) will receive 300 milligram (mg) ocrelizumab

    Drug: Ocrelizumab

  • Experimental
    Cohort 2

    Participants with a body weight \>/= 40 kg (with at least 2 participants with a body weight \>/= 40 kg but \</= 50 kg) will receive 600 mg ocrelizumab

    Drug: Ocrelizumab

  • Experimental
    Cohort 3 (optional)

    Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from \>/= 25 kg to \< 40 kg may be enrolled and receive another dose level of ocrelizumab

    Drug: Ocrelizumab

  • Experimental
    Cohort 4 (optional)

    Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight \>/= 40 kg may be enrolled and receive another dose level of ocrelizumab

    Drug: Ocrelizumab

Interventions

  • Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks. Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg

06

What researchers measure

Primary outcomes

  1. Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab

    The population PK model was used to simulate concentration-time course and predict individual area under the concentration versus time curve. The data for the PK parameter: area under the concentration versus time curve was collected and analyzed as per body weight range (\<40kg to ≥40 kg).

    Time frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113

  2. Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab

    The population PK model was used to simulate concentration-time course and predict individual Cmax. The data for the PK parameter: Cmax was collected and analyzed as per body weight range (\<40kg to ≥40 kg).

    Time frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113

  3. Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood

    Time frame: At Week 24

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product.

    Time frame: Up to 12 years

  2. Dose Exploration Period: Level of Circulating T Cells and Natural Killer (NK) Cells

    Time frame: At Week 24

  3. OOE Period: Level of Circulating T Cells and NK Cells

    Time frame: Up to 12 years

  4. Dose Exploration Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte

    Time frame: At Week 24

  5. OOE Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte

    Time frame: Up to 12 years

  6. Developmental Milestones - Growth Velocity: Change in Height

    Time frame: Up to 12 years

  7. Developmental Milestones: Bone Age Assessment by Wrist/Hand Radiographs

    Time frame: Up to 12 years

  8. Developmental Milestones: Male and Female Puberty Assessed by Tanner Staging

    Time frame: Up to 12 years

  9. Developmental Milestones: Age at Menarche, Related With the Female Reproductive Status

    Time frame: Up to 12 years

  10. Dose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)

    The change in the non-MS CNS pathology was assessed using MRI scans.

    Time frame: Up to Week 24

  11. OOE Period: Number of Participants With Shift From Baseline in Non-MS CNS Pathology as Measured by Brain MRI

    Time frame: Up to 12 years

  12. Dose Exploration Period: Levels of Blood Immunoglobulins

    Time frame: At Week 24

  13. OOE Period: Levels of Blood Immunoglobulins

    Time frame: Up to 12 years

  14. Dose Exploration Period: Number of Participants With Antibody Titers Against Standard Vaccines

    Measurement of antibody titers to common antigens (mumps, rubella, varicella, and Streptococcus pneumoniae \[S. pneumoniae\]) were performed.

    Time frame: At Week 24

  15. OOE Period: Number of Participants With Antibody Titers Against Standard Vaccines

    Time frame: Up to 12 years

  16. Dose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab

    Time frame: At Week 24

  17. OOE Period: Number of Participants With ADAs to Ocrelizumab

    Time frame: Up to 12 years

07

Results

Posted Nov 8, 2024

Participant flow

Participants took part in the study across 12 investigative sites in 3 countries (the United States, Poland, and Italy). This study is still ongoing.

Dose Exploration Period: 24 Week
Participant flow — Dose Exploration Period: 24 Week
MilestoneOcrelizumab 300 mgOcrelizumab 600 mg
Started617
Completed617
Not completed00
OOE Period: 264 Week
Participant flow — OOE Period: 264 Week
MilestoneOcrelizumab 300 mgOcrelizumab 600 mg
Started617
Completed00
Not completed617
Withdrew: Ongoing in study517
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryDose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab

The population PK model was used to simulate concentration-time course and predict individual area under the concentration versus time curve. The data for the PK parameter: area under the concentration versus time curve was collected and analyzed as per body weight range (\<40kg to ≥40 kg).

Time frame:
Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
Reported as:
Median · microgram/milliters*day (µg/mL*day)
Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab
microgram/milliters*day (µg/mL*day)Body Weight < 40 kgBody Weight ≥ 40 kg
Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab2187 (1565 to 3090)3197 (1781 to 4339)
PrimaryDose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab

The population PK model was used to simulate concentration-time course and predict individual Cmax. The data for the PK parameter: Cmax was collected and analyzed as per body weight range (\<40kg to ≥40 kg).

Time frame:
Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
Reported as:
Median · microgram/milliters (µg/mL)
Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab
microgram/milliters (µg/mL)Body Weight < 40 kgBody Weight ≥ 40 kg
Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab106 (81 to 142)158 (113 to 209)
PrimaryDose Exploration Period: Levels of CD 19+ B-cell Count in Blood
Time frame:
At Week 24
Reported as:
Median · cells/µL
Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood
cells/µLOcrelizumab 300 mgOcrelizumab 600 mg
Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood91.00 (24.0 to 404.0)9.00 (1.0 to 151.0)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product.

Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDose Exploration Period: Level of Circulating T Cells and Natural Killer (NK) Cells
Time frame:
At Week 24
Reported as:
Mean · cells/microliter (µL)
Dose Exploration Period: Level of Circulating T Cells and Natural Killer (NK) Cells
cells/microliter (µL)Ocrelizumab 300 mgOcrelizumab 600 mg
CD3+ Total T cell1637.67 ± 578.501506.0 ± 468.68
CD4+ Helper T cell1044.0 ± 329.0889.18 ± 252.58
CD8+ Cytotoxic T cell441.83 ± 180.32532.65 ± 218.52
NK cells266.5 ± 182.97237.76 ± 118.63
SecondaryOOE Period: Level of Circulating T Cells and NK Cells
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDose Exploration Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte
Time frame:
At Week 24
Reported as:
Mean · 10^9 cells/L
Dose Exploration Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte
10^9 cells/LOcrelizumab 300 mgOcrelizumab 600 mg
Lymphocyte1.792 ± 0.6601.668 ± 0.507
Neutrophil2.60 ± 0.5672.857 ± 0.762
Monocyte0.328 ± 0.1510.343 ± 0.114
Leukocyte4.87 ± 1.355.05 ± 1.06
SecondaryOOE Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDevelopmental Milestones - Growth Velocity: Change in Height
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDevelopmental Milestones: Bone Age Assessment by Wrist/Hand Radiographs
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDevelopmental Milestones: Male and Female Puberty Assessed by Tanner Staging
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDevelopmental Milestones: Age at Menarche, Related With the Female Reproductive Status
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)

The change in the non-MS CNS pathology was assessed using MRI scans.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Dose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)
ParticipantsOcrelizumab 300 mgOcrelizumab 600 mg
Dose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)00
SecondaryOOE Period: Number of Participants With Shift From Baseline in Non-MS CNS Pathology as Measured by Brain MRI
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDose Exploration Period: Levels of Blood Immunoglobulins
Time frame:
At Week 24
Reported as:
Mean · gram/liter (g/L)
Dose Exploration Period: Levels of Blood Immunoglobulins
gram/liter (g/L)Ocrelizumab 300 mgOcrelizumab 600 mg
Total Immunoglobulin11.23 ± 1.4011.86 ± 2.92
Immunoglobulin A1.27 ± 0.481.52 ± 0.61
Immunoglobulin G9.25 ± 1.209.73 ± 2.51
Immunoglobulin M0.72 ± 0.260.61 ± 0.31
SecondaryOOE Period: Levels of Blood Immunoglobulins
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDose Exploration Period: Number of Participants With Antibody Titers Against Standard Vaccines

Measurement of antibody titers to common antigens (mumps, rubella, varicella, and Streptococcus pneumoniae \[S. pneumoniae\]) were performed.

Time frame:
At Week 24
Reported as:
Count of participants · Participants
Dose Exploration Period: Number of Participants With Antibody Titers Against Standard Vaccines
ParticipantsOcrelizumab 300 mgOcrelizumab 600 mg
Mumps00
Pneumococcal Capsular Polysaccharides617
Rubella00
Varicella-Zoster Virus00
SecondaryOOE Period: Number of Participants With Antibody Titers Against Standard Vaccines
Time frame:
Up to 12 years

Results for this outcome have not been posted.

SecondaryDose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab
Time frame:
At Week 24
Reported as:
Count of participants · Participants
Dose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab
ParticipantsOcrelizumab 300 mgOcrelizumab 600 mg
Dose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab00
SecondaryOOE Period: Number of Participants With ADAs to Ocrelizumab
Time frame:
Up to 12 years

Results for this outcome have not been posted.

Adverse events

Collected over Up to 3.7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab 300 mg0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Ocrelizumab 600 mg0/17 (0%)4/17 (23.5%)17/17 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventOcrelizumab 300 mgOcrelizumab 600 mg
AppendicitisInfections and infestations1/60/17
Abdominal painGastrointestinal disorders0/61/17
Peripheral swellingGeneral disorders0/61/17
Abscess limbInfections and infestations0/61/17
Candida infectionInfections and infestations0/61/17
Gonococcal infectionInfections and infestations0/61/17
PneumoniaInfections and infestations0/61/17
Alanine aminotransferase increasedInvestigations0/61/17
Blood creatine phosphokinase increasedInvestigations0/61/17
DehydrationMetabolism and nutrition disorders0/61/17
Most frequent other events
Showing 10 of 139
Most frequent other events
EventOcrelizumab 300 mgOcrelizumab 600 mg
Infusion related reactionInjury, poisoning and procedural complications3/614/17
COVID-19Infections and infestations3/611/17
HeadacheNervous system disorders2/68/17
NasopharyngitisInfections and infestations0/67/17
PyrexiaGeneral disorders2/66/17
Upper respiratory tract infectionInfections and infestations1/66/17
Abdominal painGastrointestinal disorders2/62/17
NauseaGastrointestinal disorders2/61/17
FatigueGeneral disorders2/63/17
Disturbance in attentionNervous system disorders2/61/17

Baseline characteristics

Safety evaluable population included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Ocrelizumab 300 mgOcrelizumab 600 mgTotal
Mean11.2 ± 0.815.3 ± 1.814.2 ± 2.4
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab 300 mgOcrelizumab 600 mgTotal
Female51015
Male178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ocrelizumab 300 mgOcrelizumab 600 mgTotal
Hispanic or Latino033
Not Hispanic or Latino61420
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab 300 mgOcrelizumab 600 mgTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American011
White51621
More than one race000
Unknown or Not Reported000
Cluster of Differentiation (CD) 19+B cells
Cluster of Differentiation (CD) 19+B cells(cells/microliters (cells/µL))Ocrelizumab 300 mgOcrelizumab 600 mgTotal
Median287 (160.0 to 635.0)234 (73.0 to 512.0)246 (73.0 to 635.0)
08

Study locations

12 sites
09

References and documents

Publications

  • Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15;272(2):137. doi: 10.1007/s00415-024-12879-z. PubMed 39812825 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Oct 2023, 44 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 44 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2019
First posted
Aug 30, 2019
StartActual
Jan 9, 2020
Primary completionActual
Oct 5, 2023
CompletionEst.
Apr 26, 2032
Results first posted
Nov 8, 2024
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04075266
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 30, 2019
Start date
Jan 9, 2020
Primary completion
Oct 5, 2023
Completion
Apr 26, 2032 (estimated)
Results posted
Nov 8, 2024
Last update
Nov 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion